All News

guidelines.recommendations.jpg

Best of 2023: 2022 EULAR Recommendations for ANCA-associated Vasculitis

d Jack Cush, MD

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). AAV recommendations were last published in 2016, and since, research and clinical trials have advanced our understanding of AAV.  A EULAR task force of 20 experts from 16 countries, reviewed the literature and developed four overarching principles and 17 recommendations.

Read Article
Giants,women,rheumatology

Best of 2023: 25 Great Women in Rheumatology

d Jack Cush, MD

This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?

Read Article
labs2.jpg

Best of 2023: Time to Risk Stratify Methotrexate Lab Monitoring?

d Jack Cush, MD

A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Best of 2023: Our old friend, hydroxychloroquine

d Eric Dein, MD

After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.

Read Article
NVC in 1356 #SSc registry pts classified as early, active or‘late. Late pattern seen in 40%: signific. assoc w/ dcSSc (OR=1.96), ILD (OR=1.29), renal crisis (OR=3.46), digital ulcer (OR=1.29), & topoisomerase I Abs (OR=1.39) https://t.co/RgET0HbImf https://t.co/Ex3nKto6JW

Links:

Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study 365 RA pts showed eating half a pizza >1 time/wk (vs. ≤2 times/mo) was assoc w/ 70% less Dz activity; esp w/ more severe RA (80%) (benefit likely due to mozzarella & olive oil). YES, this was an italian study... https://t.co/1yHtS1wrtn https://t.co/xoxKK6ujdk

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Bimekizumab is Coming…in Third Place Of the many exciting advancements for patients with psoriatic arthritis at ACR23 one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. https://t.co/rhyEuyCjQI https://t.co/vbRs2144We

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Methotrexate: shall we split up? Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg. https://t.co/EQV2LeaaGB https://t.co/bD2zJbXETv

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family? Click here to answer >> https://t.co/7SgvYqFe1W

Links:

Dr. John Cush RheumNow ( View Tweet)

Promising Therapies for Sjogren's Dr. Yuz Yusof discusses abstracts 1634 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/qwRRf0sYhj https://t.co/zZACPJ96NM

Links:

Dr. John Cush RheumNow ( View Tweet)
Maryland specialty clinic eval 1395 Lyme pts & saw marked differences between blacks & whites. Black patients had 5 fold (OR 4.93) higher risk of disseminated LD & delay in Abx Rx. Dissem Dz also more likely in men (OR, 1.6) EM Rash harder to spot https://t.co/NL8yJ9CdvQ https://t.co/dUUXyWYbsT

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Eosinophilia in RA High Eosinophil counts in Stable RA - what's the differential Dx?. https://t.co/r7DHil4u9B https://t.co/rTAGUcgd1C

Links:

Dr. John Cush RheumNow ( View Tweet)
Programmed-cell-death 1 (PD-1) expression on T-cells is assoc w/ activation & exhaustion. The exhausted phenotype of PD-1+CD8+ T cells add to the pathogenesis of active idiopathic inflammatory myositis. https://t.co/xOYfEs16ou https://t.co/MzEPpUc7Eb

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 Recommendations on Fatigue Fatigue is highly prevalent in inflammatory rheumatic and musculoskeletal diseases (I-RMDs) patients, is often unaddressed and yet it has significant effects on patient quality of life. https://t.co/ETYyCnykj7 https://t.co/c2DEWrvqZb

Links:

Dr. John Cush RheumNow ( View Tweet)
RA pts more likely to get autoimmune thyroid Dz (AITD), but after dx, AITD risk signif. drops (HR 0.81), suggesting RA Rx lowers AITD risk; greater drop in biologic Rx RA (HR 0.54).Swiss registry compared 13,731 new-onset RA pts to 63,201 matched controls https://t.co/iBIreoNrXx https://t.co/xh4rWdKbGT

Links:

Dr. John Cush RheumNow ( View Tweet)
Health disparities in SLE reviewed disparities by Parodis et al. Racial and ethnic influences on manifestations and outcomes reviewed, along with common pitfalls in studies, along w/ proposed framework for research on health disparities in SLE (full read) https://t.co/rJSqLwQW1S https://t.co/w3ZpdVQYNL

Links:

Dr. John Cush RheumNow ( View Tweet)
Hemophagocytic Lymphohistiocytosis in Still's disease Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/8XvMsGtul2 https://t.co/HG0QOu5V77

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Warning on CAR-T Cell Therapy The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies. https://t.co/uxY7xgqgqn https://t.co/xyZrXXGGIy

Links:

Dr. John Cush RheumNow ( View Tweet)
Korean ULTRA registry studied 117 Gout pts starting ULT; compared T2T achievers (SUA< 6) vs non-achievers. @6 mos, 71% reached target SUA (w/ better adherence (98% vs. 76%) than non-achievers. T2T achievers assoc w/ good adherence, +FamHx, & HTN meds https://t.co/wTuvPqcan5 https://t.co/QD9j923sSa

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis shows the prevalence of self-reported sleep problems in #PsA ranged 30% to 85%. 6 studies showed poor sleep quality in 73% (statistically higher than controls 27%). Sleep ranked in the top 4 health-related quality of life domains by PsA pts. https://t.co/d79Ji3KCBu https://t.co/HJpqUIQ8x6

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×